- Trials with a EudraCT protocol (285)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (156)
285 result(s) found for: Pertussis.
Displaying page 1 of 15.
EudraCT Number: 2009-013411-36 | Sponsor Protocol Number: VTdaP-01 | Start Date*: 2009-12-08 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: Immunogenicity and safety of a tetanus, diphtheria and mono component acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as a booster vaccination t... | |||||||||||||
Medical condition: The intended use of the vaccine in this study is to increase the immunological protection against pertussis in adults who completed primary vaccination with diphtheria, tetanus and pertussis vaccin... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003838-32 | Sponsor Protocol Number: ADC01 | Start Date*: 2019-01-11 |
Sponsor Name:Sanofi Pasteur | ||
Full Title: Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults | ||
Medical condition: Tetanus Diphtheria Pertussis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-003678-42 | Sponsor Protocol Number: IIV-316 | Start Date*: 2017-09-01 |
Sponsor Name:RIVM [...] | ||
Full Title: Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands... | ||
Medical condition: Pertussis infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005273-31 | Sponsor Protocol Number: HPARSRSG12/06 | Start Date*: 2013-05-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Public Health England | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Menin... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prevention of meningitis C and pertussis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006124-64 | Sponsor Protocol Number: 111815 (DTPA-IPV(BOOSTRIX-IPV)-010 | Start Date*: 2009-02-12 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals dTpa-IPV vaccine (Boostrix Polio) compared with S... | ||||||||||||||||||||||||||||
Medical condition: Booster immunisation of healthy preschool children against diphtheria, tetanus, pertussis, poliomyelitis, mumps, measles and rubella; and first or second immunisation of healthy preschool children ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000943-26 | Sponsor Protocol Number: 115375 | Start Date*: 2011-05-12 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Completed) NO (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002452-40 | Sponsor Protocol Number: Td500056 | Start Date*: 2023-03-08 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur | ||||||||||||||||||||||||||||
Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg... | ||||||||||||||||||||||||||||
Medical condition: Bacterial infections | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001119-38 | Sponsor Protocol Number: 116945 | Start Date*: 2015-09-21 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||||||||||||
Full Title: A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. | |||||||||||||||||||||||
Medical condition: Booster immunisation against diphtheria, tetanus and pertussis diseases. The study population for this study will include pregnant women. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) FI (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-008195-13 | Sponsor Protocol Number: 2008-008195-13 | Start Date*: 2009-02-18 |
Sponsor Name:Swedish Institute for Infectious Disease Control (SMI) | ||
Full Title: An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children p... | ||
Medical condition: Two vaccines against diphtheria, tetanus and pertussis will be tested and immune respons investigated in 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005845-30 | Sponsor Protocol Number: Td506-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents (11-64 ... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005843-15 | Sponsor Protocol Number: Td9704-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five-, Eight- and Ten-Year Data on the Long- Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005844-32 | Sponsor Protocol Number: Td9805-LT | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001864-50 | Sponsor Protocol Number: IIV-268 | Start Date*: 2013-07-22 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc... | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023976-16 | Sponsor Protocol Number: Matab2 | Start Date*: 2010-02-08 |
Sponsor Name:University of Antwerp | ||
Full Title: Maternal antibodies against pertussis in neonates . | ||
Medical condition: Pertussis disease is reported in very young children who have not yet been (fully) vaccinated and did not receive sufficient maternal antibodies. Augmenting maternal antibody titers by administerin... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012219-16 | Sponsor Protocol Number: 113060 | Start Date*: 2011-04-18 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IV, open-label, non-randomised, multicentre study to assess the immunogenicity and reactogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, ... | ||||||||||||||||||||||||||||
Medical condition: Booster immunisation of healthy adults against diphtheria, tetanus, pertussis and poliomyelitis. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005532-27 | Sponsor Protocol Number: PERTIMMUN06 | Start Date*: 2006-02-07 |
Sponsor Name:Sanofi Pasteur Inc. | ||
Full Title: Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Group... | ||
Medical condition: Prophylaxis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004056-36 | Sponsor Protocol Number: Sched2 | Start Date*: 2007-12-20 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Health Protection Agency | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005842-69 | Sponsor Protocol Number: Td526 | Start Date*: 2016-01-26 | |||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
Full Title: Immune Responses in Adults to Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005355-32 | Sponsor Protocol Number: IIV-275 | Start Date*: 2014-03-06 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002976-41 | Sponsor Protocol Number: ZonMW522004008 | Start Date*: 2019-07-09 |
Sponsor Name:RIVM | ||
Full Title: ‘Premature infants and maternal pertussis immunization. Is second trimester vaccination beneficial?’ | ||
Medical condition: women in their first trimester of pregnancy | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
